Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single Doses Subcutaneous Administration of TEV-48125 (Doses up to 900 mg) in Japanese and Caucasian Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries
- 06 Jun 2021 Results of HV Study NCT02673567 ( n = 64) and the Phase 2 PTH Study NCT03347188 ( n = 87), assessing evaluation of the correlations between pretreatment plasma CGRP levels, disease characteristics and fremanezumab treatment response in patients with posttraumatic headache, presented at the 63rd Annual Scientific Meeting of the American Headache Society
- 05 Sep 2017 According to a Teva Pharmaceutical media release, data will be presented at at the 18th Congress of the International Headache Society (IHC).
- 20 Apr 2017 Status changed from active, no longer recruiting to completed.